PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC

NCT06366451 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinoma

Interventions

BIOLOGICAL: Rilvegostomig
BIOLOGICAL: Volrustomig
BIOLOGICAL: Sabestomig
BIOLOGICAL: AZD9592
BIOLOGICAL: Pembrolizumab
COMBINATION_PRODUCT: AZD9592 + Rilvegostomig
COMBINATION_PRODUCT: AZD9592 + Volrustomig
COMBINATION_PRODUCT: AZD9592 + Sabestomig
COMBINATION_PRODUCT: AZD9592 + Pembrolizumab

Sponsor

Presage Biosciences

Collaborators

[object Object]